{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-007002","form_type":"8-K","ticker":"ALGS","cik":"0001799448","company_name":"Aligos Therapeutics, Inc.","filed_at":"2022-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.164345+00:00","generated_at":"2026-06-22T15:03:29.268206+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Aligos Q3 net loss $18.6M, cash $142.3M; HBV and NASH programs advancing","bullets":["Net loss $18.6M ($0.44 per share) vs $33.1M ($0.78) a year ago; R&D spending fell to $17.8M.","Cash, equivalents, and investments $142.3M as of Sep 30, 2022, down from $205.8M at Dec 31, 2021.","HBV CAM ALG-000184 initiated up-to-48-week dosing; siRNA ALG-125755 SAD in healthy volunteers ongoing.","NASH THR-beta agonist ALG-055009 MAD data to be presented at AASLD; plans to advance to Phase 2.","Pan-coronavirus protease inhibitor ALG-097558 entering Phase 1 enabling studies; clinical eval expected Q2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-007002","json":"https://secwatch.observer/filing/0001171843-22-007002.json","markdown":"https://secwatch.observer/filing/0001171843-22-007002.md","text":"https://secwatch.observer/filing/0001171843-22-007002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799448/000117184322007002/0001171843-22-007002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799448/000117184322007002/f8k_110222.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T15:03:29.268206+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9b9a6e22ba8aea4d729311828b1f9d2fc67c2a51","claim":"Aligos Therapeutics, Inc. reported third quarter, September 30, 2022 results: net income Net losses for the three months ended September 30, 2022, were $18.6 million or basic and diluted net loss per common sh, EPS $(0.44).","evidence_excerpt":"Net losses for the three months ended September 30, 2022, were $18.6 million or basic and diluted net loss per common share of $(0.44), compared to net losses of $33.1 million or basic and diluted net loss per common share of $(0.78) for the three months ended September 30, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1799448/000117184322007002/0001171843-22-007002-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter, September 30, 2022"},{"label":"Net income","value":"Net losses for the three months ended September 30, 2022, were $18.6 million or basic and diluted net loss per common sh"},{"label":"EPS","value":"$(0.44)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}